Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:34:06.456Z.
Calculation as of: 2026-10-06T16:34:06.456Z.
Quote observation: 2026-10-06T15:40:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7a98ef6549bf85b46c4ba181efc1584300b0c5a2a31302d891700dc780dc00a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$11.58M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.61M
Price/FCF Ratio
N/A
TTM Avg
6.98
3Y Avg
6.98
5Y Avg
6.98
Market Cap
$11.66M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pluri Inc. (PLUR) | $11.54M | N/A | N/A | N/A | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.58M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.61M | N/A | 6.98 | 6.98 | 6.98 |
| Biofrontera Inc. (BFRI)vs › | $11.40M | N/A | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.66M | N/A | N/A | N/A | N/A |
| BioVie Inc. (BIVI)vs › | $11.12M | N/A | N/A | N/A | N/A |
| Caring Brands, Inc. (CABR)vs › | $11.09M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.20M | N/A | 9.96 | 9.96 | 9.96 |
| Cerenome, Inc. (CNSY)vs › | $11.01M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.58M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
